Novo Nordisk
NVO
537 hedge funds and large institutions have $7.57B invested in Novo Nordisk in 2018 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 151 increasing their positions, 192 reducing their positions, and 52 closing their positions.
33% more call options, than puts
Call options by funds: $77.7M | Put options by funds: $58.3M
0.29% more ownership
Funds ownership: 16.88% → 17.17% (+0.29%)
3% less funds holding
Funds holding: 553 → 537 (-16)
7% less capital invested
Capital invested by funds: $8.16B → $7.57B (-$594M)
21% less repeat investments, than reductions
Existing positions increased: 151 | Existing positions reduced: 192
21% less funds holding in top 10
Funds holding in top 10: 14 → 11 (-3)
23% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$97.5M |
| 2 |
D.E. Shaw & Co
New York
|
+$35.7M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$33.3M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$26.9M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$21.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$129M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$72M |
| 3 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$71.7M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$35.2M |
| 5 |
BlackRock
New York
|
-$28.5M |
NVO Hedge Fund Activity: Q2 2018 in Review
537 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2018, worth a combined $7.57B — down 7.3% from $8.16B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of NVO and 40 opened new positions — a net loss of 12 holders — while 192 trimmed existing stakes and 151 added.
The largest buyer was Renaissance Technologies, adding an estimated $97.5M. The largest seller was Fidelity Investments, cutting an estimated $129M.
- 537 institutional investors held Novo Nordisk (NVO) as of Q2 2018, down from 553 in Q1 2018.
- Funds reported $7.57B of Novo Nordisk stock for Q2 2018, down 7.3% quarter-over-quarter.
- 40 funds opened new Novo Nordisk positions in Q2 2018 and 52 closed out, a net change of -12 holders.
- The largest Novo Nordisk buyer in Q2 2018 was Renaissance Technologies, an estimated $97.5M added.
- The largest Novo Nordisk seller in Q2 2018 was Fidelity Investments, an estimated $129M sold.
Based on aggregated 13F filings for Q2 2018.